scholarly journals Combining Gene and Stem Cell Therapy for Peripheral Nerve Tissue Engineering

2017 ◽  
Vol 26 (4) ◽  
pp. 231-238 ◽  
Author(s):  
Francesca Busuttil ◽  
Ahad A. Rahim ◽  
James B. Phillips
2020 ◽  
Vol 195 ◽  
pp. 108982 ◽  
Author(s):  
Yi-Wen Chen ◽  
Kan Wang ◽  
Chia-Che Ho ◽  
Chia-Tze Kao ◽  
Hooi Yee Ng ◽  
...  

2015 ◽  
Vol 15 (6) ◽  
pp. 612-621 ◽  
Author(s):  
Lorena R. Lizarraga-Valderrama ◽  
Rinat Nigmatullin ◽  
Caroline Taylor ◽  
John W. Haycock ◽  
Frederik Claeyssens ◽  
...  

2018 ◽  
Vol 301 (10) ◽  
pp. 1657-1667 ◽  
Author(s):  
Papon Muangsanit ◽  
Rebecca J. Shipley ◽  
James B. Phillips

2011 ◽  
Vol 175-176 ◽  
pp. 220-223 ◽  
Author(s):  
Ai Jun Hu ◽  
Bao Qi Zuo ◽  
Feng Zhang ◽  
Qing Lan ◽  
Huan Xiang Zhang

Schwann cells (SCs) are primary structural and functional cells in peripheral nervous system and play a crucial role in peripheral nerve regeneration. Current challenge in peripheral nerve tissue engineering is to produce an implantable scaffold capable of bridging long nerve gaps and assist Scs in directing the growth of regenerating axons in nerve injury recovery. Electrospun silk fibroin nanofibers, fabricated for the cell culture in vitro, can provide such experiment support. Silk fibroin scaffolds (SFS) were fabricated with formic acid (FA), and the average fiber diameter was 305 ± 24 nm. The data from microscopic, immunohistochemical and scanning electron micrograph confirmed that the scaffold was beneficial to the adherence, proliferation and migration of SCs without exerting any significant cytotoxic effects on their phenotype. Thus, providing an experimental foundation accelerated the formation of bands of Bünger to enhance nerve regeneration. 305 nm SFS could be a candidate material for nerve tissue engineering.


Author(s):  
Somayeh Tofighi Nasab ◽  
Nasim Hayati Roodbari ◽  
Vahabodin Goodarzi ◽  
Hossein Ali Khonakdar ◽  
Kourosh Mansoori ◽  
...  

Author(s):  
Jahnavi Sarvepalli ◽  
Rajalakshmi Santhakumar ◽  
Rama Shanker Verma

The incidence of cardiovascular disease (CVD) in adults are increasing worldwide with impaired repair mechanisms, leading to tissue and organ failure. With the current advancements, life expectancy has improved and has led to search for new treatment strategies that improves tissue regeneration. Recently, stem cell therapy and tissue engineering has captured the attention of clinicians, scientists, and patients as alternative treatment options. The overall clinical experience of these suggests that they can be safely used in the right clinical setting. Ultimately, large outcome trials will have to be conducted to assess their efficacy. Clinical trials have to be carefully designed and patient safety must remain the key concern. At the same time, continued basic research is required to understand the underlying mechanism of cell-based therapies and cell tissue interactions. This chapter reviews the evolving paradigm of stem cell therapy and tissue engineering approaches for clinical application and explores its implications.


Sign in / Sign up

Export Citation Format

Share Document